Nature of Business and Financial Condition (Details)					1 Months Ended	12 Months Ended
	Apr. 12, 2021 USD ($)	Mar. 31, 2021 USD ($)	Mar. 19, 2021 USD ($)	Dec. 08, 2020	Mar. 31, 2021 USD ($)	Jun. 30, 2021 USD ($) product	Jun. 30, 2020 USD ($)
Nature of Business and Financial Condition
Revenue from contract with customer						$ 65,632,000	$ 27,632,000
Restructuring costs						4,886,000	667,000
Accounts receivable, net						28,176,000	5,633,000
Accrued liabilities						51,295,000	8,831,000
Cash, cash equivalents and restricted cash						49,900,000
Net loss						(58,289,000)	(13,621,000)
Accumulated deficit						(178,299,000)	(120,010,000)
Net cash used in operating activities						(25,964,000)	(28,374,000)
Current assets						105,234,000	75,422,000
Aytu Consumer Health
Nature of Business and Financial Condition
Revenue from contract with customer						$ 32,954,000	10,383,000
Number of products | product						30
Net loss						$ (7,760,000)	$ (3,157,000)
Reverse Stock Split
Nature of Business and Financial Condition
Stock split, conversion ratio				10
Neos Therapeutics, Inc.
Nature of Business and Financial Condition
Repayments of long-term debt			$ 15,400,000
Payments for merger related costs			$ 5,500,000
Acerus
Nature of Business and Financial Condition
Termination agreement, aggregate amount		$ 7,500,000			$ 7,500,000
Termination agreement, monthly installment payments		$ 250,000
Termination agreement, equal monthly installment payment, period					30 months
In-process R&D | Rumpus
Nature of Business and Financial Condition
Cash transferred	$ 1,500,000
Payment of aggregated fees	600,000
Contingent consideration	$ 67,500,000